Fiscal 2023 – 3rd Quarter Results

Earnings Conference Call Supplement

Wednesday, August 9, 2023 @ 10AM ET





Safe Harbor Statements and Important Information

Forward-Looking Statements

Statements in this presentation that are not historical, including statements relating to the expected future performance of the Company, are considered "forward looking" within the meaning of the federal securities laws and are presented pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements because they contain words such as "believes," "expects," "will," "should," "would," "could," "seeks," "approximately," "intends," "projects," "oloking forward," or similar expressions that relate to our strategy, plans, intentions, or expectations. All statements we make relating to our estimated and projected earnings, margins, costs, expenditures, tash flows, growth rates, and financial results or to our expectations regarding future industry trends are forward-looking statements. In addition, we, through our senior management, from time to time make forward-looking public statements concerning our expected future operations and performance and other developments.

Our actual results may differ materially from those that we expected due to a variety of factors, including without limitation: (1) risks associated with our substantial indebtedness and debt service; (2) changes in prices and availability of resin and other raw materials and our ability to pass on changes in raw material prices to our customers on a timely basis; (3) risks related to acquisitions or divestitures and integration of acquired businesses and their operations, and regulations, sand regulations, sincluding transactional and translational foreign currency exchange rate risk and the risks of compliance with applicable export controls, sanctions, anti-corruption laws and regulations; (5) increases in the cost of compliance with laws and regulations, including environmental, safety, and climate change laws and regulations; (6) labor issues, including the potential labor shortages, shutdowns or strikes, or the failure to renew effective bargaining agreements; (7) risks related to disruptions in the overall global economy, persistent inflation, supply chain disruptions, and the financial markets that may adversely impact our business, including as a result of the Russia-Ukraine conflict; (8) risk of catastrophic loss of one of our key manufacturing facilities, natural disasters, and other unplanned business interruptions; (9) risks related to weather-related events and longer-term climate change patterns; (10) risks related to the failure of, inadequacy of, or attacks on our information technology systems and infrastructure; (11) risks related to the failure of, inadequacy of, or attacks on our information technology systems and infrastructure; (11) risks related to the failure of, inadequacy of, or attacks on our information technology systems and infrastructure; (12) risks related to future write-offs of substantial goodwill; (13) risks of competition, including foreign competition

These slides are not intended to be a stand-alone presentation, but are for use in conjunction with the earnings call. This presentation should be read together with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the consolidated financial statements and the related notes thereto included in our public filings.

Non-GAAP Financial Measures

This presentation includes certain non-GAAP financial measures such as operating EBITDA, adjusted EBITDA, adjusted net income, free cash flow, and supplemental unaudited financial information intended to supplement, not substitute for, comparable measures under generally accepted accounting principles in the United States (GAAP). Information reconciling forward-looking operating EBITDA is not provided because such information is not available without unreasonable effort due to the high variability, complexity, and low visibility with respect to certain Items, including debt refinancing activity or other non-comparable items. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP. Intensection accordance with GAAP measures and the reconciliations to those measures provided in our earnings release, presentations, and SEC filings. For further information about our non-GAAP measures, please see our earnings release, SEC filings and supplemental data at the end of this presentation. Further, percentage changes for revenue, Operating EBITDA, and Adjusted EPS are shown on "comparable basis" with the prior year period, which excludes the impacts of foreign currency along with any recent divestitures. We believe this comparison provides meaningful and useful information to investors about the trends in our businesses and clarifies the impact of non-recurring items.



Berry at a Glance

• NYSE ('BERY')

• FY'22 Revenue: \$14.5B

• FY'22 Adj. EPS: \$7.40

• Locations: 250+

• Employees: 46,000

• Consumer Products: >70%



Global leader in packaging for consumer staples and industrial products




Stable end markets with favorable longterm dynamics




flows

Sustainabilit

Sustainability Leader





Emerging Markets





Key Takeaways for Today

- 1. FY'23 guidance within our provided range; cost reduction initiatives offsetting softer customer demand including destocking
- 2. Additional cost actions of \$25M taken in the quarter now totaling \$140M in annualized savings \$75M expected to be realized in FY'23, \$55M in FY'24, and \$10M in FY'25
- 3. Returned \$513M of capital to shareholders YTD: \$416M of shares repurchased (or 5.6% of s/o) along with our quarterly dividend payments totaling \$97M
- 4. Continue to expect repurchasing $\frac{$600M}{}$ of shares in FY'23; Long-term leverage target range of 2.5x-3.5x to be achieved in FY'24

Focus on driving long-term shareholder value



Fiscal 3rd Quarter & YTD Results





Industry Trends Driving Organic Growth

These markets offer higher growth (MSD-HSD) and higher margins

Faster Growth Markets

Healthcare, personal care/beauty, and foodservice

Targeting 40% of the portfolio

Emerging Markets

Continued focus on higher consumption demographics

Targeting 25% of the portfolio

Sustainability Innovation

PCR, circular polymers, light-weighting along with differentiated products

Targeting 30% circular feedstock

Grown these select end markets from ~20% to now 30%*

Grown emerging markets from <2% to now 15%*

Grown sustainability resins by ~66% over the past 5 years and expected continued growth rate of 20% YOY



New Healthcare Site Expansion **Bangalore, India**




Cleanstream® PCR Technology Expansion
Leamington Spa, UK



Q3 FY 2023 Results

Consumer Packaging International



Revenue

 Softer consumer and industrial market demand in Europe, including destocking partially offset by improved product mix to higher value products

Op. EBITDA

- Cost reduction efforts, along with improved product mix by increasing our presence in healthcare packaging, pharmaceutical devices, and dispensing systems
- Continued focus on high value segments and sustainable product offerings




Growth Product Mix Ex.

Healthcare / Pharma/ Dispensing

Q3 FY 2023 Results

Consumer Packaging North America







Revenue


 Pass-through of lower resin prices in the U.S., softer overall customer demand primarily in our industrial markets along with our concentrated effort to improve our sales mix to higher value products partially offset by strong volumes in foodservice.

Op. EBITDA

 Softer overall customer demand and the timing impact of higher polymer prices in the U.S., which is expected to be recovered in the September quarter, partially offset by improved cost productivity from structural cost reductions and our focus to higher value products such as foodservice, closures, and dispensing systems



Q3 FY 2023 Results Engineered Materials



Growth Product Mix Ex. Ultra Performance transportation film Consumer film

Revenue


 Pass through of lower resin prices in the U.S. and volume softness primarily in European industrial markets along with customer destocking. Additionally volumes were impacted by our concentrated effort to improve our sales mix to higher value products

Op. EBITDA

- Softer customer demand offset by improved product mix to higher value product categories and structural cost reduction initiatives
- Continued focus on mix improvement and productivity



Q3 FY 2023 Results Health, Hygiene, & Specialties



Revenue

 Pass-through of lower resin prices and ongoing inventory destocking along with softer demand inside many of our specialties markets such as filtration and building and construction markets

Op. EBITDA

• In-line with our expectations; improvement initiatives were offset with weaker demand in some of our higher value specialty markets



Growth Product Mix Ex.

Adult incontinence

Feminine care

Healthcare

FY '23 Guidance

Continued focus on driving long-term shareholder value



Expect \$600M or more of share repurchases in FY'23

(~8% of shares outstanding)

Other modeling items

- Operating EBITDA: \$2.05B
- Depreciation expense: \$575M
- Interest expense: \$315M
- Other expense: \$50M
- Effective tax rate: 20%
- Average diluted shares: 121.5M




Capital Allocation Strategy

Opportunistic and return-based focus

- Investing in growth markets (Returns well above our WACC)
 - Healthcare
- Sustainability-focused products
- Pharmaceutical
- Dispensing solutions
- Beauty care
- Foodservice
- **Returning capital to shareholders** (>\$700M expected in FY23)
- Continued focus on reducing leverage

Strong and Dependable Free Cash Flow





~\$3 billion

Debt ReductionSince the RPC acquisition


~\$1.4 billion

Capital Return to Shareholders

Repurchasing \$1.3 B of shares (~18% of s/o) while adding a long-term growing dividend

Maximizing Value Creation

\$4.3B of returned value to shareholders over last 4 years






Proven and Resilient Portfolio

	FY'15	FY'22	CAGR
Revenue	\$4,881	\$14,495	17%
Operating EBITDA ⁽¹⁾	\$815	\$2,101	15%
Adjusted EPS (1)	\$1.70	\$7.40	23%
Adjusted FCF (1)	\$436	\$876	10%

Resilient results through any economic cycle;
Positioned for continued revenue, earnings,
and free cash flow growth

Adj. EPS CAGR



Unlike our peers we have grown our annual Adj. EPS every single year




Path to Success – Attractive Investment Opportunity

Historical Speculated Valuation Gap Causes

- ✓ Peer average volume growth ➤
- **✓** Share repurchases
- ✓ Dividend
- ✓ Leverage & LT target range
- **√ S&P Index** (inclusion on 06/20/23)

Strategy has brought volumes in-line with peers



We believe our valuation gap will continue to shrink



Focused Investment for Growth

Dispensing solutions



Healthcare



Foodservice





Circular materials

Berry

Pharmaceutical


India



Personal care



Long-Term Targets



Delivering on targets – enabled by organic growth focus

Key Investment Highlights



Global leader in packaging for consumer staples and industrial products



Proven growth platform



Sustainability leader



Low cost manufacturer of thousands of products in stable end markets

Strong, growing, dependable, and predictable cash flows



Berry's Business Model To Drive Value Into The Future



Broad global portfolio

> Access to global customer base and emerging markets

Share repurchases and a growing quarterly dividend

Return of capital to shareholders

Consistent & Dependable Free Cash Flow Investing in sustainable organic growth

- > Enhanced focus on healthcare, foodservice, and beauty/personal care markets
- > Innovation and sustainabilityfocused products

Decades of consolidation opportunities, fragmented markets; leverage our scale = significant cost synergies (i.e. sourcing, locations, equipment)

Market consolidation









Berry

Q&A3rd Quarter - Fiscal Year 2023
Earnings Conference Call




Safety

- Safety of our people is our #1 priority
- Best-in-class safety performance

110 sites

With **ZERO**Recordable Incidents


"Safety doesn't happen by accident"



Never ending commitment to identifying, managing, and minimizing risk



Appendix: Fiscal Q3 Net Sales and Operating EBITDA Bridge





Non-GAAP Reconciliation

Segment and Supplemental Comparable Basis Information (Unaudited)

(in millions of USD)		Quarterly Period Ended July 1, 2023						
	Consumer Packaging - International	Consumer Packaging- North America	Health, Hygiene & Specialties	Engineered Materials	Total			
Net sales	\$ 1,036	\$ 798	\$ 657	\$ 738	\$ 3,229			
Operating income Depreciation and amortization	\$ 68 79	\$ 89 54	\$ 22 45	\$ 88 29	\$ 267 207			
Restructuring and transaction activities	17	6	12	2	37			
Other non-cash charges Operating EBITDA	6 \$ 170	\$ 151	\$ 81	\$ 120	\$ 522			

			Quarte	rly Period	Ended July	2, 2022		
Reported net sales	\$ 1,096	\$	927	\$	788	\$	915	\$ 3,726
Foreign currency and divestitures	(20)		13		7		1	1
Comparable net sales (1)	\$ 1,076	\$	940	\$	795	\$	916	\$ 3,727
Operating income	\$ 82	\$	104	\$	56	\$	94	\$ 336
Depreciation and amortization	78		53		44		28	203
Restructuring and transaction activities	3		1		3		_	7
Other non-cash charges	_		1		2		1	4
Foreign currency and divestitures	(2)		5		(4)		(2)	(21)
Comparable operating EBITDA (1)	\$ 161	S	164	\$	105	\$	123	\$ 553

⁽¹⁾ The prior year comparable basis change excludes the impacts of foreign currency, acquisitions, and divestitures. Further details related to non-GAAP measures and reconciliations can be found under our "Non-GAAP Financial Measures and Estimates" section or in reconciliation tables in this release.



Non-GAAP Reconciliation

Reconciliation of adjusted earnings before interest, tax, depreciation and amortization (EBITDA), Net income, and earnings per share (EPS) on millions of USO, except per share data amounts)

	Quarterly Pe	riod Ended	Three Quarterly Periods Ended		
	July 1,	July 2,	July 1,	July 2,	
	2023	2022	2023	2022	
Net income	\$143	\$207	\$ 423	\$ 533	
Add: other expense	11	7	13	13	
Add: interest expense	78	70	228	212	
Add: income tax expense	35	52	114	148	
Operating income	\$267	\$336	\$ 778	\$ 906	
Add: restructuring and transaction activities	37	7	74	18	
Add: other non-cash charges	11	4	48	18	
Adjusted operating income (2)	\$315	\$347	\$ 900	\$ 942	
Add: depreciation	146	140	425	424	
Add: amortization of intangibles	61	63	181	196	
Operating EBITDA (2)	\$522	\$550	\$1,506	\$1,562	
Net income per diluted share	\$ 1.18	\$ 1.58	\$ 3.47	\$ 3.93	
Other expense, net	0.09	0.05	0.11	0.10	
Restructuring and transaction activities	0.31	0.06	0.61	0.13	
Amortization of intangibles from acquisitions (1)	0.50	0.48	1.48	1.45	
Income tax impact on items above	(0.18)	(0.14)	(0.44)	(0.40)	
Foreign currency, acquisitions, and divestitures	, ,	0.01		(0.12)	
Adjusted net income per diluted share (2)	\$ 1.90	\$ 2.04	\$ 5.23	\$ 5.09	

Note: All dollar amounts in millions, except per share data. Unaudited

- (1) Amortization of intangibles from acquisition are added back to better align our calculation of adjusted EPS with peers.
- (2) Supplemental financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures should not be considered as alternatives to operating or net income or cash flows from operating activities, in each case determined in accordance with GAAP. Organic sales growth and comparable basis measures exclude the impact of currency translation effects and acquisitions. These non-GAAP financial measures may be calculated differently by other companies, including other companies in our industry, limiting their usefulness as comparative measures. Berry's management believes that adjusted net income and other non-GAAP financial measures are useful to our investors because they allow for a better period-over-period comparison of operating results by removing the impact of items that, in management's view, do not reflect our core operating performance.

We define "free cash flow" as cash flow from operating activities, less net additions to property, plant, and equipment. We believe free cash flow is useful to an investor in evaluating our liquidity because free cash flow and similar measures are widely used by investors, securities analysts, and other interested parties in our industry to measure a company's liquidity. We also believe free cash flow is useful to an investor in evaluating our liquidity as it can assist in assessing a company's ability to fund its growth through its generation of cash.

Adjusted EBITDA is used by our lenders for debt covenant compliance purposes. We also use Adjusted EBITDA, Operating EBITDA, and comparable basis measures, among other measures, to evaluate management performance and in determining performance-based compensation. Operating EBITDA is a measure widely used by investors, securities analysts, and other interested parties in our industry to measure a company's performance. We also believe EBITDA and Adjusted net income are useful to an investor in evaluating our performance without regard to revenue and expense recognition, which can vary depending upon accounting methods.



Non-GAAP Reconciliation

	FY 2015
Net income	\$86
Add: other expense (income), net	95
Add: interest expense, net	191
Add: income tax expense	36
Operating income	\$408
Add: non-cash amortization from 2006 private sale	32
Add: restructuring and transaction activities (1)	36
Add: other non-cash charges (2)	21
Adjusted operating income (4)	\$497
Add: depreciation	259
Add: amortization of intangibles (3)	59
Operating EBITDA (4)	\$815
Net income per diluted share	\$0.70
Other expense (income), net	0.77
Non-cash amortization from 2006 private sale	0.26
Restructuring and transaction activities	0.29
Income tax impact on items above	(0.32)
Adjusted net income per diluted share (4)	\$1.70
Cash flow from operations	637
Net additions to PP&E	(162)
Payment on TRA	(39)
Adjusted free cash flow ⁽⁴⁾	\$436

- (1) Includes primarily integration expenses and other business optimization costs.
- (2) Primarily includes stock compensation expense.
- (3) Amortization excludes non-cash amortization from the 2006 private sale of \$32 million for fiscal year ended September 26, 2015.
- (4) Supplemental financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures should not be considered as alternatives to operating or net income or cash flows from operating activities, in each case determined in accordance with GAAP. These non-GAAP financial measures are among the indicators used by management to measure the performance of the Company's operations, and also among the criteria upon which performance-based compensation may be based. Adjusted EBITDA also is used by our lenders for debt covenant compliance purposes. We use Adjusted Free Cash Flow as a measure of liquidity because it assists us I n assessing our Company's ability to fund its growth through its generation of cash. Our projected Adjusted Free Cash flow for fiscal 2016 assumes \$817 million of cash flow from operations less \$285 million of additions to property, plant, and equipment and \$57 million of payments under our tax receivable agreement.

Similar non-GAAP financial measures may be calculated differently by other companies, including other companies in our industry, limiting their usefulness as comparative measures. Because of these limitations, you should consider the non-GAAP financial measures alongside other performance measures and liquidity measures, including operating income, various cash flow metrics, net income and our other GAAP results.





Dustin M. Stilwell

VP, Investor Relations

Berry Global Group, Inc.

101 Oakley Street, 3rd floor P. O. Box 959

Evansville, IN 47706

Tel: +1.812.306.2964

ir@berryglobal.com

www.berryglobal.com

